"...imaging tumors early can improve how clinicians develop personalized treatment plans for each patient."

"Once we identified the mechanism causing the colitis, we could then develop ways to overcome this problem..."

Glioblastoma is one of the most treatment-resistant cancers. A new study offers clues as to how it can aggressively resist immunotherapy.

In mouse models of different cancers, a new drug slowed tumor growth, extended lifespan, and boosted the efficacy of immunotherapy.

Fusing a molecular tail onto the engineered T cells used in immunotherapy can inhibit their proclivity to attack each other, say researchers.

"We hypothesized that the newer treatment would turn out to be most beneficial for patients, but the magnitude of the benefit exceeded our expectations."

Researchers have discovered for the first time how deadly hard-to-treat breast cancers persist after chemotherapy.

Researchers have found a process in glioblastoma brain tumors that drives resistance to immune-boosting therapies.

A combination immunotherapy significantly slowed liver cancer growth and enhanced the strength of tumor-attacking T cells in mice, researchers say.

Implantable "drug factories" that kill advanced-stage ovarian and colorectal cancer in mice in six day could be ready for human clinical trials this fall.